Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Study Details
Study Description
Brief Summary
RATIONALE: Collecting and storing samples of tissue, blood, and body fluid from patients with cancer to study in the laboratory may help the study of cancer in the future.
PURPOSE: This research study is collecting and storing blood and tissue samples from patients being evaluated for hematologic cancer.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
OBJECTIVES:
-
Provide source of patient tissue, blood, and body fluid samples for ongoing diagnostic, prognostic, or immune-monitoring studies.
-
Support and enhance translational, clinical and basic research for Lineberger Comprehensive Cancer Center (LCCC) members (and non-members who have an LCCC member as sponsor and collaborator) with IRB-approved studies.
-
Maintain responsible and appropriate policies and procedures that ensure good patient care and responsible conduct of research.
-
Address medical and legal issues, and protect participant and patient privacy and confidentiality.
-
Provide a responsible and uniform mechanism for the integrated coordination of the hemato-pathologist and surgeon or hematology/oncology staff, researcher, and protocol office to obtain appropriate specimens for researchers.
-
Support young investigators to obtain pilot data for grant funding.
OUTLINE: Patients undergo tissue, blood, and body fluid collection during diagnostic or routine procedures for future correlative studies. Tissue samples may include, but are not limited to, lymph node or non-nodal biopsies, bone marrow biopsy and/or aspirate, blood and serum, and buccal swabs for germline DNA analysis.
Study Design
Outcome Measures
Primary Outcome Measures
- Tissue, blood, and body fluid samples collection for ongoing diagnostic, prognostic, or immune-monitoring studies [30 years]
- Development of a centralized, quality-controlled, quality-assured facility for the procurement, processing, storage, and distribution of normal and malignant tissue specimens and corresponding blood specimens [30 years]
Eligibility Criteria
Criteria
DISEASE CHARACTERISTICS:
-
Diagnosis of abnormal hematopoietic/lymphoid cancer, including any of the following:
-
Acute myeloid leukemia
-
Acute lymphoblastic leukemia
-
Chronic myelogenous leukemia
-
Chronic lymphoid leukemia
-
Non-Hodgkin lymphoma
-
Hodgkin lymphoma
-
Myelodysplastic syndromes
-
Myeloproliferative disorders
-
Multiple myeloma
-
Waldenstrom macroglobulinemia
-
Aplastic anemia
-
Any other diseases that generate abnormalities in either number, function, or both of any cell type of hematolymphoid lineage
-
Patients who are being evaluated at the hematology/oncology clinics of the University of North Carolina Hospitals, at the stem cell transplant clinic, or in the hospital
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- Not specified
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill | Chapel Hill | North Carolina | United States | 27599-7295 |
Sponsors and Collaborators
- UNC Lineberger Comprehensive Cancer Center
- National Cancer Institute (NCI)
Investigators
- Principal Investigator: Paul Armistead, MD, UNC Lineberger Comprehensive Cancer Center
Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
None provided.- LCCC 0824
- P30CA016086
- CDR0000674072